August 2022—Beckman Coulter and Scopio Labs announced a worldwide partnership to accelerate the adoption of Scopio’s next-generation peripheral blood smear platforms. Scopio’s technology uses full-field imaging and AI decision support to eliminate manual microscopy.
“By leveraging computational photography, Scopio generates a high-resolution, full-field image of the sample, including a large scan area and the smallest details. This is a leap in digital morphology capabilities, and with easy and secure remote viewing, can help laboratories significantly reduce manual labor burden while improving turnaround time,” Peter Soltani, PhD, senior vice president and general manager at Beckman Coulter, said in a press statement. “We are excited to partner with Scopio Labs to bring cutting-edge digital peripheral blood smear analysis and the use of AI decision support to our customers, continuing our push to innovate and solve everyday problems for the lab.”
Scopio’s Full-Field Peripheral Blood Smear morphology solution captures large scan areas at 100× magnification. The X100HT holds 30 slides and processes up to 40 samples an hour and fully supports remote review capabilities. Scopio Labs received FDA 510(k) clearance of its X100HT device with PBS application in May.
Beckman Coulter, 714-993-5321
Scopio Labs, 631-637-4113